Diabetes

Five things for pharma marketers to know: Wednesday, July 20, 2016

Five things for pharma marketers to know: Wednesday, July 20, 2016

By By

Spending on CME rose in 2015; the FDA approves Valeant's Relistor; the Justice Department aims to block insurer merger

Five things for pharma marketers to know: Wednesday, June 15, 2016

Five things for pharma marketers to know: Wednesday, June 15, 2016

By

Hospitals struggle with high drug costs; the FDA approves new weight loss device; the ADA asks docs not to tweet, but they did anyway

How a startup is educating kids with diabetes with a teddy bear

How a startup is educating kids with diabetes with a teddy bear

By

Sproutel CEO Aaron Horowitz talks about how Jerry the Bear came to life and why endocrinologists are stocking the bear in their offices.

Five things for pharma marketers to know: Monday, June 13, 2016

Five things for pharma marketers to know: Monday, June 13, 2016

By By

A new Sanofi combination diabetes drug meets clinical trial targets; IBM partners with the American Diabetes Association; Dr. Reddy's to buy eight Teva drugs

Following positive outcomes data, a new diabetes class is on the rise

Following positive outcomes data, a new diabetes class is on the rise

By

Eli Lilly noted in its first-quarter earnings report that SGLT2 inhibitors, a treatment for type 2 diabetes patients, are surging.

Five things for pharma marketers to know: Tuesday, April 12, 2016

Five things for pharma marketers to know: Tuesday, April 12, 2016

By

California bill would require price disclosures; AbbVie's and Genentech's blood-cancer drug is approved; FDA expands metformin use

MannKind reworks commercial strategy for Afrezza

MannKind reworks commercial strategy for Afrezza

By

After buying back the rights to the therapy, the biopharmaceutical company is building a endocrinology sales force and hiring a new advertising agency.

Devicemakers eye market for drug adherence

Devicemakers eye market for drug adherence

By

Insulet's skin-adhesive technology is being used to improve adherence for patients taking biologics.

Five things for pharma marketers to know: Friday, February 5, 2016

Five things for pharma marketers to know: Friday, February 5, 2016

By

Johnson & Johnson collaborates with biotech on diabetes stem-cell treatment; the FDA warms up to Remicade biosimilar; Woodcock warns about biosimilar backlog

Diabetes R&D narrows in on glycemic control

Diabetes R&D narrows in on glycemic control

By

New entrants in the type 2 diabetes treatment market share a similar goal: To solve patients' constant struggle with glycemic control.

Marketing challenges remain in crowded metabolic market

Marketing challenges remain in crowded metabolic market

By

Experts insist that R&D efforts in the category must mirror educational campaigns and lifestyle changes, and quickly.

Five things for pharma marketers to know: Tuesday, January 26, 2016

Five things for pharma marketers to know: Tuesday, January 26, 2016

By

The FDA accepts bid for new label for Jardiance; Markey puts on a hold on Califf's FDA nomination; GSK is studying the Zika virus

American Girl: Pharma's New Empathy Model

American Girl: Pharma's New Empathy Model

By

The kits aren't likely to enhance American Girl's bottom line in any significant way, yet the flood of press coverage painted the company as compassionate in a way that few such organizations are.

Five things for pharma marketers to know: Wednesday, January 6, 2016

Five things for pharma marketers to know: Wednesday, January 6, 2016

By

Lilly's Jardiance starting to gain market share; Merck "raring" to make acquisitions; Sanofi said it will stop marketing Afrezza

Sanofi to stop marketing Afrezza, citing low Rx

Sanofi to stop marketing Afrezza, citing low Rx

By

Sanofi spent $3.75 million on advertising for Afrezza in the third quarter of 2015 yet the therapy only brought in about $2 million in revenue.

Lantus competitor receives FDA approval

Lantus competitor receives FDA approval

By

Eli Lilly and Boehringer Ingelheim received approval to begin selling their Lantus knock-off drug after settling a patent lawsuit with Sanofi in September.

Five things for pharma marketers to know: Thursday, December 17, 2015

Five things for pharma marketers to know: Thursday, December 17, 2015

By

The FDA approves Lilly's Lantus follow-on biologic; AstraZeneca buys majority stake in Acerta Pharma; Shkreli arrested on securities fraud charges

Five things for pharma marketers to know: Tuesday, December 8, 2015

Five things for pharma marketers to know: Tuesday, December 8, 2015

By

Certain insulins are comparable; Public Citizen criticizes Cures provision on orphan-drug exclusivity; the FDA approves Kanuma

Five things for pharma marketers to know: Monday, December 7, 2015

Five things for pharma marketers to know: Monday, December 7, 2015

By

Gleevec generic is approved; FDA issues warning on diabetes drugs; Senate will hold hearing on drug pricing

Diabetes launches aid Lilly's Q3 sales growth

Diabetes launches aid Lilly's Q3 sales growth

By

The drugmaker recently launched a DTC campaign for diabetes drug Trulicity, which generated $73.7 million in sales in the third quarter.

Lilly kicks off DTC campaign for Trulicity

Lilly kicks off DTC campaign for Trulicity

By

The drugmaker aims to differentiate its type-2 diabetes drug in the competitive GLP-1 receptor agonist class.

BI and Lilly launch DTC campaign for Jardiance

BI and Lilly launch DTC campaign for Jardiance

By

The drugmakers worked with Evoke Health to develop a campaign that would differentiate the third-in-class type-2 diabetes drug in an increasingly competitive market.

Five things for pharma marketers to know: Friday, September 18, 2015

Five things for pharma marketers to know: Friday, September 18, 2015

By

Oncologist says cancer drug prices defy markets; Jardiance slashes cardiovascular risk by one-third; Allergan wins approval for antipsychotic

Google and Sanofi partner in diabetes

Google and Sanofi partner in diabetes

By

The search giant and the drugmaker will develop new tools to monitor the disease and improve patient outcomes.

Five things for pharma marketers to know: Thursday, August 27

Five things for pharma marketers to know: Thursday, August 27

By

The FDA releases biosimilar-naming draft guidance; PD1 drugs linked to a rare type of diabetes; Amgen's PCSK9 inhibitor faces approval decision

Diabetes device firm Intarcia taps former ICC Lowe CEO Viviano as marketing lead

Diabetes device firm Intarcia taps former ICC Lowe CEO Viviano as marketing lead

By

Longtime ICC leader Viviano moves to the client side to help the start-up build its marketing team and become a commercial contender.

New data sets up Jardiance  to displace DPP-4 inhibitors

New data sets up Jardiance to displace DPP-4 inhibitors

By

Eli Lilly's and BI's diabetes medication Jardiance becomes the first blood glucose-lowering drug to demonstrate it can reduce the risk of heart attack and stroke.

Five things for pharma marketers to know: Friday, August 7

Five things for pharma marketers to know: Friday, August 7

By

CVS excludes 31 drugs including Viagra from its 2016 formulary; Sanofi partners with Evotec on stem-cell treatment development; primary-care physicians may hesitate to prescribe Truvada for PrEP

Novo Nordisk says any tussle with Sanofi's Toujeo will come down to formulary access

Novo Nordisk says any tussle with Sanofi's Toujeo will come down to formulary access

By

The Danish drugmaker said it expects an FDA decision about long-acting—and long-delayed—insulin Tresiba in October.

Sanofi launches DTC campaign for Afrezza

Sanofi launches DTC campaign for Afrezza

By

The "Surprise, it's insulin" campaign follows criticism of the lower-than-expected sales of the inhaled insulin since its launch in February.

OPINION

Email Newsletters